ReviewAdvances in therapy2020
Psoriasis and Cardiovascular Risk: A Comprehensive Review.
Review in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 3 syntheses or guidelines pooled it, 198 citations in OpenAlex.
- Associations between psoriasis and risk of 33 cancers: a Mendelian randomization study.BMC cancer · 2025Pooled it
- A mixed methods systematic review of digital interventions to support the psychological health and well-being of people living with dermatological conditions.Frontiers in medicine · 2022Pooled it
- Association between psoriasis and coronary artery calcification: A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Exploring the role of neuro-immune modulation for psoriasis management: a narrative review of existing evidence and future therapies.Brain, behavior, & immunity - health · 2026Review
- Cumulative Duration of Severe Psoriasis: A Novel Cardiovascular Risk Predictor for Dermatologists.Dermatology and therapy · 2026Article
- Joint Relationship of Cardiovascular-kidney-metabolic Syndrome and Psoriasis with All-cause and Cause-specific Mortality in Adults: A Population-based Analysis.Acta dermato-venereologica · 2026Article
- Article
- Biological Therapy Leads to a Reduction in Systemic Inflammation but Leaves Serum Uric Acid Unmodified in Moderate-to-Severe Plaque Psoriasis: A Prospective Longitudinal Cohort Study.Journal of clinical medicine · 2026Article
- Neutrophil-to-Lymphocyte Ratio as a Predictor of Cardiovascular Events in Psoriatic Disease: A Retrospective Cohort Study.ACR open rheumatology · 2026Article
- Cell-type-specific causal effects of CEBPD in CD8 + S100B + Tcells and ZFP36 in monocytes modulate the protective and risk phenotypes in psoriasis.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.AAPS PharmSciTech · 2026Review
- The Heart of Psoriasis: Cardiovascular Alterations and Common Inflammatory Mechanisms.Current cardiology reviews · 2026Review
- Application of Trichoscopy and Novel Non-Invasive Imaging Techniques in the Diagnosis and Management of Patients with Scalp Psoriasis.Psoriasis (Auckland, N.Z.) · 2026Review
- The Psoriatic Disease Assessment Index (PSODAI) Score to Evaluate Systemic Involvement of Psoriasis.Psoriasis (Auckland, N.Z.) · 2026Article
- Review
- Lipoprotein (a) levels are elevated in psoriasis: An updated systematic review and meta-analysis.World journal of clinical cases · 2025Article
- Single-cell multi-omics of ribosome biogenesis-related genes reveals immune microenvironment in psoriasis and constructs a diagnostic model.Clinical and experimental medicine · 2025Article
- Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.JAMA dermatology · 2025Article
- NLRP3-inflammasome Related Genes as Emerging Biomarkers and Therapeutic Targets in Psoriasis.Inflammation · 2025Article
- Erectile dysfunction in dermatology and venereology: From aetiopathogenic mechanisms to practical considerations for dermato-venereologists.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a systemic inflammatory disorder that involves complex pathogenic interactions between the innate and adaptive immune systems. Individuals with psoriasis have an increased risk of developing other chronic health diseases such cardiovascular disorders. The high incidence of cardiovascular events in the population with psoriasis could be explained by several mechanisms. The high prevalence of traditional cardiovascular risk factors and metabolic abnormalities contributes to the high cardiovascular burden in patients with psoriasis. Likewise, the presence of systemic inflammation in combination with metabolic abnormalities may act in a synergistic manner to increase cardiovascular risk in these patients. This review focused on epidemiologic and clinical evidence linking psoriasis to cardiovascular risk factors and cardiovascular disease. We described the possible pathophysiological mechanisms that justify this association and analyzed the best way to stratify the cardiovascular risk in patients with psoriasis. We also described the usefulness of the therapies frequently used in cardiovascular prevention and analyzed the impact of the specific psoriasis medication on cardiovascular risk factors or major atherosclerotic events. Knowledge of the application of different cardiovascular prevention strategies could mean an advantage in performing the difficult task of estimating cardiovascular risk and treating cardiovascular risk factors in this particular group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.